SEATTLE--(BUSINESS WIRE)--Sound Pharmaceuticals is pleased to announce that the pivotal Phase 3 clinical trial involving SPI-1005, a novel anti-inflammatory compound (ebselen), for the treatment of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback